Revive Therapeutics Provides Update of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19 - Marketscreener.com
| THCT Stock | USD 0.0005 0.00 0.00% |
Slightly above 55% of THC Therapeutics' private investors are presently thinking to get in. The analysis of overall sentiment of trading THC Therapeutics pink sheet suggests that some investors are interested at this time. THC Therapeutics' investing sentiment can be driven by a variety of factors including economic data, THC Therapeutics' earnings reports, geopolitical events, and overall market trends.
THC |
Revive Therapeutics Provides Update of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19 Marketscreener.com
Read at news.google.com
 |
THC Therapeutics Fundamental Analysis
We analyze THC Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of THC Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of THC Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Shares Owned By Insiders
Shares Owned By Insiders Comparative Analysis
THC Therapeutics is currently under evaluation in shares owned by insiders category among its peers. Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
THC Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with THC Therapeutics pink sheet to make a market-neutral strategy. Peer analysis of THC Therapeutics could also be used in its relative valuation, which is a method of valuing THC Therapeutics by comparing valuation metrics with similar companies.
Peers
THC Therapeutics Related Equities
| ESALF | Eisai Co | 0.10 | ||||
| MKGAF | MERCK Kommanditgesells | 3.82 | ||||
| CXXIF | C21 Investments | 4.17 |
Additional Tools for THC Pink Sheet Analysis
When running THC Therapeutics' price analysis, check to measure THC Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy THC Therapeutics is operating at the current time. Most of THC Therapeutics' value examination focuses on studying past and present price action to predict the probability of THC Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move THC Therapeutics' price. Additionally, you may evaluate how the addition of THC Therapeutics to your portfolios can decrease your overall portfolio volatility.